On this page
AHK-Cu Quick Reference (100 mg Vial)
- Vial contents
- 100 mg AHK-Cu
- Final volume
- 3 mL
- Concentration
- 33.33 mg/mL
- One U-100 unit
- 333.33 mcg in 0.01 mL
AHK-Cu Dosage Chart
Dosing & Reconstitution Guide
Community-Reported Use Calculations (3.0 mL = 33.33 mg/mL)
Community-Reported Use Calculations (3.0 mL = 33.33 mg/mL)
| Research Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| 8 weeks | 1 mg | 3 units (0.03 mL) |
| 12 weeks | 1 mg | 3 units (0.03 mL) |
| 8 weeks | 2 mg | 6 units (0.06 mL) |
| 12 weeks | 2 mg | 6 units (0.06 mL) |
Frequency: Once daily by subcutaneous injection in the reviewed community descriptions. Each row is an independent calculation, not a titration schedule.
Research reference only: The 1 to 2 mg once-daily, 8 to 12 week patterns are nonclinical community descriptions. Reports varied from lower to substantially higher amounts and included daily, intermittent, topical, and uncertain routes. No human AHK-Cu trial establishes these numbers, and the cited mouse patent used intradermal rather than subcutaneous injection.
Reconstitution Steps
- Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
- Draw exactly 3.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with compound, concentration, and reconstitution date. Refrigerate at 2–8 °C (36–46 °F) and protect from light.
Storage note: Avoid repeated freeze-thaw cycles. No AHK-Cu-specific post-reconstitution stability or discard period has been established; follow the lot-specific supplier documentation for any discard date.
Supplies Needed
Choose the supply row that matches the single calculation period being reviewed. Do not add the rows together.
- Peptide Vials (AHK-Cu, 100 mg each):
- 8 weeks at 1 mg/day: 1 vial
- 12 weeks at 1 mg/day: 1 vial
- 8 weeks at 2 mg/day: 2 vials
- 12 weeks at 2 mg/day: 2 vials
- Insulin Syringes (U-100):
- 8-week calculations: 56 syringes
- 12-week calculations: 84 syringes
- Bacteriostatic Water (10 mL bottle):
- One-vial calculations: 3.0 mL
- Two-vial calculations: 6.0 mL
- Alcohol Swabs:
- 8-week calculations: 112 swabs
- 12-week calculations: 168 swabs
Sharps safety: Place used needles and syringes immediately in an approved sharps container.
Peptide Reconstitution Simulator
Practice preparing this vial with the verified strength and final volume from this protocol.
AHK-Cu Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water for a calculated concentration of approximately 33.33 mg/mL.
- Vial contents: 100 mg AHK-Cu.
- U-100 conversion: At 33.33 mg/mL, 1 unit = 0.01 mL = approximately 333.33 mcg.
- Storage: Refrigerate at 2–8 °C (36–46 °F) and protect from light.
Direct peer-reviewed AHK-Cu evidence used human hair follicles ex vivo and dermal papilla cells in vitro.[1] An animal patent also reported intradermal injection in mice, but neither source validates a human subcutaneous or intravenous protocol.[6]
AHK-Cu Injection Research Context
The direct peer-reviewed AHK-Cu paper reported follicle elongation in human hair follicles maintained ex vivo and dermal papilla cell proliferation in vitro at molar concentrations.[1] It did not administer AHK-Cu to people. A separate U.S. patent described intradermal AHK-Cu injection experiments in C3H mice, including 0.75 mg and 1.5 mg per injection groups.[6] That animal route was intradermal, not intravenous, and it does not validate the community-reported subcutaneous schedule shown above.
Hair-follicle cycling is controlled by complex epithelial, mesenchymal, hormonal, and signaling interactions.[2] The available models do not establish human pharmacokinetics, systemic exposure, safety, or clinical benefit.
AHK-Cu Is Not GHK-Cu
AHK-Cu and GHK-Cu are different tripeptide-copper complexes. The broader GHK-Cu literature may be useful for comparison, but it does not validate an AHK-Cu dose, route, efficacy claim, or safety profile.[3]
100 mg Vial Calculation Notes
- 100 mg divided by 3.0 mL equals approximately 33.33 mg/mL. Calculate syringe volumes from the unrounded concentration.
- One U-100 unit equals 0.01 mL or approximately 333.33 mcg.
- 1 mg equals 3 units (0.03 mL).
- 2 mg equals 6 units (0.06 mL).
Evidence and Safety Limits
No peer-reviewed human clinical trial identified in this review established an AHK-Cu injectable dose, route, frequency, duration, pharmacokinetic profile, or safety profile.[1][3] The 1 to 2 mg once-daily, 8 to 12 week rows are community descriptions kept separate from the academic references. Reported injection amounts, schedules, routes, and tolerability varied materially, so none of the rows should be described as recommended, standard, validated, or safe.
Peptide identity, impurity profile, copper stoichiometry, sterility, pH, exposure, and clinical pharmacology require compound- and formulation-specific evidence.[4][5]
References
- 1Pyo et al., 2007, PMID 17703734 – Direct AHK-Cu study using human hair follicles ex vivo and dermal papilla cells in vitro at 10^-12 to 10^-9 M. It did not test a human topical or injectable dose.
- 2Stenn and Paus, 2001, PMID 11152763 – Review of controls governing hair-follicle cycling and the limits of translating follicle biology into treatment claims.
- 3Pickart and Margolina, 2018, PMID 29986520 – Review of GHK-Cu biology. GHK-Cu is a different copper peptide and this source does not validate AHK-Cu dosing.
- 4U.S. FDA, Clinical Pharmacology Considerations for Peptide Drug Products – Regulatory guidance describing clinical pharmacology evidence expected for peptide drug development.
- 5European Medicines Agency, Development and Manufacture of Synthetic Peptides – Scientific guideline addressing identity, manufacture, quality, and impurity control for synthetic peptides.
- 6U.S. Patent 6,017,888, Examples 12 and 16 – Preclinical AHK-Cu hair-growth experiments using intradermal injection in mice. This patent does not establish a human subcutaneous or intravenous protocol.